Key Takeaway: In advanced breast cancer, resistance no longer has to wait for a scan to reveal it. A blood test can detect the mutation that signals a therapy is losing effect, and a 2026 approval allows treatment to change at that point rather than after progression shows on an image. For health plans, the work is making sure coverage criteria, claims visibility and safety monitoring keep pace with a decision that now happens sooner.
A woman with metastatic breast cancer has been stable for months. Her scans show no new growth. Her next oncology visit is supposed to be routine. Then a blood draw finds something the scan can't see yet.
A small piece of tumor DNA circulating in her blood shows the cancer has changed. The treatment keeping it stable is losing its hold. Nothing has grown. Not yet.
For decades, that was the moment patients and clinicians had to wait for: the scan showing the cancer had progressed, and the search for what came next. Now, for some patients with advanced breast cancer, clinicians may see resistance emerging before it appears on an image and change course while the rest of the treatment still works.
Two FDA approvals this year sit behind that shift. Both treat the same mutation. Only one changes when the treatment decision gets made, and that's the one a plan sponsor should watch: it asks a benefit to cover a molecular test for a patient who appears stable, then authorize a specialty medication before conventional evidence of progression arrives.
For patients, that can mean more time before the cancer grows again. For plan sponsors, it raises a harder question: how do you manage a benefit when the most important signal arrives before the visible event?
Why Breast Cancer Isn't Treated as One Disease Anymore
Apart from skin cancer, breast cancer is the most commonly diagnosed cancer among U.S. women. But "breast cancer" no longer tells a clinician enough to choose treatment.
The most common advanced subtype, hormone receptor-positive and HER2-negative, is fueled by estrogen, so first-line treatment often combines an aromatase inhibitor, which lowers estrogen, with a CDK4/6 inhibitor, which slows cancer-cell division. For many patients, the combination works for a long time. Then the cancer adapts.
One of the most common mechanisms is an acquired mutation in the estrogen receptor gene, known as ESR1. The mutation lets tumor cells keep responding as though estrogen were still present, even when treatment has cut off the supply.
The patient may still feel well. The scans may still look unchanged. But the biology has moved ahead of the image.
Two New Breast Cancer Drugs, Two Different Moments in Care
In May, the FDA approved Veppanu (vepdegestrant) for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer that has progressed after at least one line of endocrine therapy. It's a protein degrader, designed to mark the estrogen receptor for destruction rather than simply block it. In the trial, patients went a median of 5.0 months before their cancer progressed, compared with 2.1 months on fulvestrant. Veppanu follows the sequence oncology has always used. Progression shows on a scan, and the next line of therapy begins.
Etcamah (camizestrant), approved on an accelerated basis in September, moves that decision earlier. Patients on first-line aromatase inhibitor and CDK4/6 inhibitor therapy are tested every three months for tumor DNA in the blood. If that test finds an ESR1 mutation while imaging still shows no progression, the aromatase inhibitor is replaced with Etcamah and the CDK4/6 inhibitor continues unchanged.
In the SERENA-6 trial, that early switch extended median progression-free survival to 16.0 months, compared with 9.2 for patients who stayed on the prior regimen.
Both drugs carry cardiac monitoring requirements, and Etcamah comes with the FDA's strongest warning about combining it with other medications that affect heart rhythm.
How Blood-Based Testing Changes Pharmacy Benefit Design
These are specialty oncology therapies, priced accordingly. Veppanu launched at a list price of $29,400 for a 30-day supply, the order of magnitude this class carries. Etcamah is also an oral drug managed through the specialty pharmacy benefit, while the testing that identifies eligible patients runs through the medical benefit.
So yes, pharmacy costs rise when a patient switches from a low-cost aromatase inhibitor to a branded specialty drug, and regular testing adds a recurring expense.
But the alternative isn’t no cost.
Without an earlier signal, resistance surfaces only once the cancer progresses on a scan. At that point the patient may need a broader change in treatment, more monitoring and a more complicated next line of care. The SERENA-6 trial shows that switching at the molecular signal can delay that progression. It doesn't yet answer whether serial testing and earlier switching reduce total cost of care.
Three Questions Plan Sponsors & Their Brokers Should Ask About ESR1 Testing and Coverage
This isn't a traditional prior authorization scenario. The patient's diagnosis hasn't changed. Their scan may not have changed. What changed is the tumor's molecular behavior. That makes three questions worth putting to a PBM partner now, while the category is still forming.
- Do coverage criteria reflect the specific FDA-approved use, including the required treatment history and an FDA-authorized test?
- Can the plan connect the test result and the treatment switch across medical and pharmacy claims, given that the test runs through one benefit and the drug through the other?
- Are oncology providers and members getting the safety support these therapies require, including attention to cardiac-risk warnings and drug interactions?
What Comes Next
Etcamah is the first FDA-approved cancer therapy directed by detection of a resistance mutation in blood before imaging shows progression. It won't be the last.
More will arrive paired with precise biomarkers, narrower populations and more complicated sequences of testing and monitoring.
The question isn't whether a plan can spot resistance before a scan does. It's whether its coverage rules can respond when an oncologist and an FDA-authorized blood test do.
FAQs
What is an ESR1 mutation in breast cancer?
ESR1 is the gene for the estrogen receptor. In hormone receptor-positive, HER2-negative advanced breast cancer, tumors can acquire a mutation in that gene during treatment, which lets the cancer keep growing as though estrogen were still available even though therapy has cut off the supply. It is one of the most common reasons first-line endocrine therapy stops working, and it develops in roughly 40% of patients treated with an aromatase inhibitor and a CDK4/6 inhibitor.
Is ESR1 testing covered under the pharmacy benefit or the medical benefit?
The testing and the drug usually sit on opposite sides. Blood-based testing is typically billed to the medical benefit, while the oral therapy it leads to runs through the specialty pharmacy benefit. That split is why a plan looking at one claim system sees only half the decision, and why evaluating this strategy requires looking at medical and pharmacy claims together.
Does switching treatment earlier improve survival?
Not proven yet. In the SERENA-6 trial, switching at the molecular signal extended median progression-free survival to 16.0 months, compared with 9.2 months for patients who stayed on their prior regimen. That measures time before the cancer grows again, not length of life. Overall survival data is not yet mature, which is why Etcamah received accelerated rather than full approval.
What safety monitoring do these therapies require?
Both carry cardiac monitoring expectations. Etcamah comes with a boxed warning about arrhythmia risk when combined with other medications that prolong the QT interval, and ribociclib, one of the CDK4/6 inhibitors it can be paired with, is itself one of those medications. Veppanu carries a QT warning of its own, including a baseline ECG before starting. Because the interacting medications are often prescribed outside the oncology practice, the member's full medication list matters.
The pharmacy benefit story moves fast. Keep the whole picture in view.
The Pharmacy Benefit Brief delivers perspective on cost, policy, and member protection. One email, once a month.
The view from inside the benefit
Expert insights from pharmacists and PBM operators with an inside view of where pharmacy decisions break down, what those gaps cost, and how they affect benefit performance.
.jpg)
See the whole pharmacy picture.
Send us your claims data and we'll show you the avoidable cost and clinical risk hiding in it.